CPT code 0482U designates a Proprietary Laboratory Analyses (PLA) test: the Preeclampsia sFlt‑1/PlGF Ratio (PERA) from Mayo Clinic. The test quantifies serum sFlt‑1 and PlGF and reports their ratio to stratify short‑term risk of severe preeclampsia progression, informing clinical monitoring and risk assessment in pregnant patients. As a PLA code, 0482U applies uniquely to a single manufacturer's or laboratory's test, which has implications for payer coverage policies, laboratory billing, and clinical adoption.

Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise national view of what CPT code 0482U represents, why it matters for maternal‑fetal care pathways, and the categories of information typically examined in coverage and billing reviews: clinical utility, placement within maternal care workflows, coding specificity due to PLA designation, and implications for laboratory service lines. The publication outlines benchmarks and policy considerations relevant to payers and billing professionals, summarizes clinical context for interpreting the sFlt‑1/PlGF ratio, and identifies areas where payer policy language commonly appears. Data not available in the input include payer‑specific coverage criteria, reimbursement rates, and associated ICD‑10 diagnosis mappings.